Celsion (CLSN) Downgraded by ValuEngine

ValuEngine lowered shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a report published on Thursday.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Celsion from a buy rating to a hold rating in a research report on Thursday, January 11th. Oppenheimer assumed coverage on shares of Celsion in a research report on Tuesday, November 21st. They issued an outperform rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Celsion has an average rating of Buy and a consensus target price of $11.90.

Celsion (NASDAQ CLSN) opened at $2.58 on Thursday. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC acquired a new stake in Celsion Co. (NASDAQ:CLSN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned 0.24% of Celsion at the end of the most recent reporting period. 3.84% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://ledgergazette.com/2018/03/18/celsion-clsn-downgraded-by-valuengine.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply